Department of Pediatrics, Milton S. Hershey Penn State Medical Center, Hershey, Pennsylvania (W.E.); Division of Pharmaceutical Chemistry and Technology, University of Helsinki, Helsinki, Finland (E.J., J.M., M.F.); Pediatric Genomics Discovery Program, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut (W.J., A.G.S., M.K., S.A.L.); Departments of Pathology and Cell Biology (A.C.I.) and Surgery (S.J.L.), Columbia University Medical Center, New York, New York; and Department of Pediatrics, University of Rochester Medical Center, Rochester, New York (A.C.).
Department of Pediatrics, Milton S. Hershey Penn State Medical Center, Hershey, Pennsylvania (W.E.); Division of Pharmaceutical Chemistry and Technology, University of Helsinki, Helsinki, Finland (E.J., J.M., M.F.); Pediatric Genomics Discovery Program, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut (W.J., A.G.S., M.K., S.A.L.); Departments of Pathology and Cell Biology (A.C.I.) and Surgery (S.J.L.), Columbia University Medical Center, New York, New York; and Department of Pediatrics, University of Rochester Medical Center, Rochester, New York (A.C.)
Drug Metab Dispos. 2019 Jan;47(1):45-48. doi: 10.1124/dmd.118.084368. Epub 2018 Nov 1.
Uridine diphosphate glucuronosyltransferases (UGTs) are key enzymes responsible for the body's ability to process a variety of endogenous and exogenous compounds. Significant gains in understanding UGT function have come from the analysis of variants seen in patients. We cared for a Sudanese child who showed clinical features of type 1 Crigler-Najjar syndrome (CN-1), namely severe unconjugated hyperbilirubinemia leading to liver transplantation. CN-1 is an autosomal recessive disorder caused by damaging mutations in the gene for UGT1A1, the hepatic enzyme responsible for bilirubin conjugation in humans. Clinical genetic testing was unable to identify a known pathogenic mutation in this child. Instead, a novel homozygous variant resulting in an in-frame deletion, p.Val275del, was noted. Sanger sequencing demonstrated that this variant segregated with the disease phenotype in this family. We further performed functional testing using recombinantly expressed UGT1A1 with and without the patient variant, demonstrating that p.Val275del results in a complete lack of glucuronidation activity, a hallmark of CN-1. Sequence analysis of this region shows a high degree of conservation across all known catalytically active human UGTs, further suggesting that it plays a key role in the enzymatic function of UGTs. Finally, we note that the patient's ethnicity likely played a role in his variant being previously undescribed and advocate for greater diversity and inclusion in genomic medicine.
尿苷二磷酸葡萄糖醛酸基转移酶(UGTs)是负责机体处理各种内源性和外源性化合物的关键酶。对患者中所见变异体的分析极大地增进了我们对 UGT 功能的理解。我们曾治疗过一名苏丹儿童,其表现出 1 型克里格勒-纳贾尔综合征(CN-1)的临床特征,即严重的未结合高胆红素血症导致肝移植。CN-1 是一种常染色体隐性疾病,由负责人类胆红素结合的肝酶 UGT1A1 基因的破坏性突变引起。临床遗传学检测未能在该儿童中识别出已知的致病性突变。相反,发现了一种新的纯合变异,导致框内缺失 p.Val275del。Sanger 测序表明,该变异在该家族中与疾病表型共分离。我们进一步使用表达有和没有患者变异的重组 UGT1A1 进行功能测试,证明 p.Val275del 导致完全缺乏葡萄糖醛酸化活性,这是 CN-1 的标志。该区域的序列分析显示,所有已知具有催化活性的人类 UGT 都具有高度的保守性,进一步表明它在 UGT 的酶功能中起着关键作用。最后,我们注意到患者的种族可能在其变异体以前未被描述方面发挥了作用,并倡导在基因组医学中实现更大的多样性和包容性。